A comparative, single-blind, randomized study on quetiapine and aripiperazole augmentation in treatment of selective serotonin reuptake inhibitor refractory obsessive-compulsive disorder
Authors:
- 1 April 2020
- journal article
- research article
- Published by Canadian Science Publishing in Canadian Journal of Physiology and Pharmacology
- Vol. 98 (4) , 236-242
Abstract
Obsessive-compulsive disorder (OCD) is a chronic psychiatric disorder, of unknown etiology, that affects 2.5% of the population. An appropriate therapeutic response to conventional treatment is seen. Some studies use augmentative treatment by antipsychotics, glutamatergic, lithium, buspirone, and others agents to improve the therapeutic response. In this study, we aimed to evaluate the efficacy and tolerability of aripiprazole and quetiapine as augmentative treatments in patients with selective serotonin reuptake inhibitor (SSRI) refractory OCD. The OCD patients were initially treated for 12 weeks with a SSRI. If after 12 weeks their Yale–Brown Obsessive-Compulsive Scale (Y-BOCS) score was more than 16, they were randomly assigned to either the aripiprazole or the quetiapine augmentation group for an additional 12 weeks. There were no significant differences in age, sex, education, marital status, or score of Y-BOCS and Clinical Global Impression-Severity Scale (CGI-S) between groups (p > 0.05) at the outset of the study. Significant differences were noted after 1 month when compared with results at 2, 3, and 4 months in both groups (p < 0.001). Both quetiapine and aripiprazole may be effective and well-tolerated augmentative agents in the treatment of SSRI-refractory OCD. Because of positive results, aripiprazole may be considered more effective and may have a more rapid onset in terms of therapeutic response.Keywords
This publication has 52 references indexed in Scilit:
- EFFECTS OF ARIPIPRAZOLE AUGMENTATION IN TREATMENT-RESISTANT OBSESSIVE-COMPULSIVE DISORDER (A DOUBLE BLIND CLINICAL TRIAL)Depression and Anxiety, 2012
- Aripiprazole Augmentation in Patients with Resistant Obsessive Compulsive Disorder: a Pilot StudyClinical Practice & Epidemiology in Mental Health, 2011
- Effect of Aripiprazole Augmentation of Serotonin Reuptake Inhibitors or Clomipramine in Treatment-Resistant Obsessive-Compulsive DisorderJournal of Clinical Psychopharmacology, 2011
- The comparison of aripiprazole and risperidone augmentation in selective serotonin reuptake inhibitor‐refractory obsessive‐compulsive disorder: a single‐blind, randomised studyHuman Psychopharmacology: Clinical and Experimental, 2011
- Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive–compulsive disorder: a 12-week open-label preliminary studyInternational Clinical Psychopharmacology, 2009
- Quetiapine Addition to Serotonin Reuptake Inhibitors in Patients With Severe Obsessive-Compulsive DisorderJournal of Clinical Psychopharmacology, 2008
- 8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive–compulsive disorderEuropean Neuropsychopharmacology, 2008
- Augmentation of Behavior Therapy With d -Cycloserine for Obsessive-Compulsive DisorderAmerican Journal of Psychiatry, 2008
- Risperidone and Haloperidol Augmentation of Serotonin Reuptake Inhibitors in Refractory Obsessive-Compulsive DisorderThe Journal of Clinical Psychiatry, 2005
- Quetiapine Augmentation in Obsessive-Compulsive Disorder Resistant to Serotonin Reuptake InhibitorsThe Journal of Clinical Psychiatry, 2005